Cancer BiologybioRxivPreprint
Pharmacologic decoupling of IRBC activation from anabolic collapse redefines ribosome biogenesis inhibition as a selective tumor suppressive strategy
Sandra Menoyo, Berta Forcada, Zoi Mastora…·Antonio Gentilella
This study shows that inhibiting ribosome biogenesis can selectively activate the IRBC checkpoint in TP53-proficient cells, offering a new therapeutic strategy for cancer.
DOI 10.64898/2026.08.24.744089